Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 4
2009 5
2010 4
2011 8
2012 5
2013 13
2014 4
2015 4
2016 3
2017 2
2018 5
2019 3
2020 1
2021 10
2022 10
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
Viviani S, Vanazzi A, Frassoni S, Rusconi C, Rossi A, Romano A, Patti C, Schiavotto C, Sorasio R, Marasco V, Lissandrini L, Rapezzi D, Gottardi D, Cocito F, Mulè A, Leotta S, Gini G, Sorio M, Derenzini E, Rambaldi A, Bagnardi V, Tarella C. Viviani S, et al. Among authors: derenzini e. Leuk Lymphoma. 2024 Apr;65(4):460-471. doi: 10.1080/10428194.2023.2298273. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164812
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. Among authors: derenzini e. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: derenzini e. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 No abstract available.
[18 F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma.
Travaini LL, Botta F, Derenzini E, Lo Presti G, Ferrari ME, Airò Farulla LS, Radice T, Mazzara S, Tarella C, Pileri S, Raimondi S, Ceci F. Travaini LL, et al. Among authors: derenzini e. Hematol Oncol. 2023 Oct;41(4):674-682. doi: 10.1002/hon.3171. Epub 2023 May 20. Hematol Oncol. 2023. PMID: 37209024 Free article.
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL.
Mazzara S, Travaini L, Botta F, Granata C, Motta G, Melle F, Fiori S, Tabanelli V, Vanazzi A, Ramadan S, Radice T, Raimondi S, Lo Presti G, Ferrari ME, Jereczek-Fossa BA, Tarella C, Ceci F, Pileri S, Derenzini E. Mazzara S, et al. Among authors: derenzini e. Blood Adv. 2023 Feb 28;7(4):630-643. doi: 10.1182/bloodadvances.2022007825. Blood Adv. 2023. PMID: 36806558 Free PMC article.
Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study.
De Filippi R, Marcacci G, Derenzini E, Musso M, Donnarumma D, Morelli E, Patti C, Maraglino AME, Scalone R, Simeone L, Becchimanzi C, Mele S, Crisci S, Morabito F, Pinto A. De Filippi R, et al. Among authors: derenzini e. Cancers (Basel). 2022 Nov 27;14(23):5846. doi: 10.3390/cancers14235846. Cancers (Basel). 2022. PMID: 36497328 Free PMC article.
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort.
Merli M, Ferrarini I, Merli F, Busca A, Mina R, Falini B, Bruna R, Cairoli R, Marchetti M, Romano A, Cavo M, Arcaini L, Trentin L, Cattaneo C, Derenzini E, Fracchiolla NS, Marchesi F, Scattolin A, Billio A, Bocchia M, Massaia M, Gambacorti-Passerini C, Mauro FR, Gentile M, Mohamed S, Della Porta MG, Coviello E, Cilloni D, Visani G, Federici AB, Tisi MC, Cudillo L, Galimberti S, Gherlinzoni F, Pagano L, Guidetti A, Bertù L, Corradini P, Passamonti F, Visco C. Merli M, et al. Among authors: derenzini e. Hematol Oncol. 2023 Feb;41(1):128-138. doi: 10.1002/hon.3092. Epub 2022 Oct 25. Hematol Oncol. 2023. PMID: 36265128 Free PMC article. Clinical Trial.
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.
Rodríguez M, Alonso-Alonso R, Fernández-Miranda I, Mondéjar R, Cereceda L, Tráscasa Á, Antonio-Da Conceiçao A, Borregón J, Gato L, Tomás-Roca L, Bárcena C, Iglesias B, Climent F, González-Barca E, Camacho FI, Mayordomo É, Olmedilla G, Gómez-Prieto P, Castro Y, Serrano-López J, Sánchez-García J, Montes-Moreno S, García-Cosío M, Martín-Acosta P, García JF, Planelles M, Quero C, Provencio M, Mahíllo-Fernández I, Rodríguez-Pinilla SM, Derenzini E, Pileri S, Sánchez-Beato M, Córdoba R, Piris MA. Rodríguez M, et al. Among authors: derenzini e. EJHaem. 2022 May 3;3(3):722-733. doi: 10.1002/jha2.457. eCollection 2022 Aug. EJHaem. 2022. PMID: 36051055 Free PMC article.
82 results